A test of the model that RNA polymerase III transcription is regulated by selective induction of the 110 kDa subunit of TFIIIC

Fiona Innes, Ben Ramsbottom and Robert J. White1,*

Institute of Biomedical and Life Sciences, Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow G12 8QQ, UK and 1Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK

Received March 6, 2006; Revised May 31, 2006; Accepted June 1, 2006

ABSTRACT

TFIIIC is a RNA polymerase (pol) III-specific DNA-binding factor that is required for transcription of tRNA and 5S rRNA genes. Active human TFIIIC consists of five subunits. However, an inactive form has also been isolated that lacks one of the five subunits, called TFIIIC110. A model was proposed in which pol III transcription might be regulated by the specific induction of TFIIIC110, allowing formation of active TFIIIC from the inactive form. We have tested this model by transient transfection of HeLa and HEK293 cells with a vector expressing TFIIIC110. We have also made stably transfected HeLa cell lines that carry a doxycycline-inducible version of the cDNA for TFIIIC110. We show that the induced TFIIIC110 enters the nucleus, binds other TFIIIC subunits and is recruited to tRNA and 5S rRNA genes in vivo. However, little or no effect is seen on the expression of pol III transcripts. The data argue against the model that pol III transcription can be effectively modulated through the specific induction of TFIIIC110.

INTRODUCTION

TFIIIC is a large DNA-binding factor that directly recognizes the promoter sequences found within most pol III-transcribed genes, including tRNA and 5S rRNA genes, and the adenoviral VA genes (1–3). It is also required for transcription of 5S rRNA genes, although in this case its recruitment is dependent on an additional polypeptide called TFIIIA (1–3). Indeed, it is probable that TFIIIC is used by all pol III templates in the yeast Saccharomyces cerevisiae, although it is not necessary for pol III transcription of mammalian U6 and 7SK RNA genes (1–3).

Human TFIIIC has been purified from HeLa cells as a complex of five subunits (4–6). These are commonly referred to as TFIIIC220, TFIIIC110, TFIIIC102, TFIIIC90 and TFIIIC63, according to their approximate molecular masses. An alternative nomenclature of TFIIICα, β, γ, δ and ε has also been used (7). The complex is stable, as the subunits remain associated following immunoprecipitation and washing in 1 M NaCl (8). Cloning of cDNAs for all five subunits has allowed confirmation that each is a bona fide component of TFIIIC (6,8–11). However, the complex has also been purified with the TFIIIC110 subunit missing (5). Furthermore, calculations based on metabolic labeling suggested that TFIIIC from cycling HeLa cells contains half as much TFIIIC110 as TFIIIC220 (7). TFIIIC complexes with or without the 110 kDa subunit were dubbed TFIIIC2a and TFIIIC2b, respectively, and shown to be resolved on non-denaturing gels or by gradient chromatography (5,9,12). Although the two forms produced identical footprints and had similar DNA-binding affinities, the complex without TFIIIC110 was unable to support transcription (5,12). These observations lead to a model in which TFIIIC activity could be regulated by reversible interaction of the TFIIIC110 subunit with the remainder of the complex (Figure 1). The interaction might be controlled by phosphorylation, as TFIIIC2b could be generated by phosphatase treatment of fractions containing active TFIIIC2a (12). The model was proposed to explain pol III transcriptional induction observed when HeLa cells are stimulated with serum or with adenoviral E1A (5,9,12).

The E1A oncoprotein of adenovirus can stimulate pol III transcription, probably through several complementary mechanisms (5,9,12–20). Hoeffler et al. (12) reported that the ratio of active TFIIIC2a to inactive TFIIIC2b, as measured by electrophoretic mobility shift assay (EMSA), is higher in HeLa cells infected with wild-type adenovirus than in cells infected with the E1A deletion mutant dl312. In support of this, western blotting revealed lower levels of TFIIIC110 following dl312 infection, compared with wild-type virus (9). EMSA analysis also suggested that the ratio of TFIIIC2a to TFIIIC2b is elevated in the E1A-transformed...
human embryonic kidney cell line 293 and in two SV40-transformed lines of murine fibroblasts (12,21). Subsequent studies found that all five subunits of TFIIIC are overexpressed in the SV40-transformed fibroblasts compared to untransformed parental cells, although the effect appears strongest for TFIIIC110 (22,23).

The rate of synthesis of pol III products is influenced strongly in mammalian cells by serum availability. Hoeffler et al. (12) reported that the relative proportion of TFIIIC2a to TFIIIC2b was reduced in HeLa cells grown in low serum, an effect which correlated with the reduced transcriptional activity. Consistent with this, western blotting revealed a decrease in expression of TFIIIC110 under low serum conditions, whereas TFIIIC220 levels were unchanged (9). A selective change in TFIIIC110 expression was therefore proposed as a mechanism allowing the pol III machinery to adapt to serum availability.

The model in Figure 1 was based on correlative data—relatively high ratios of TFIIIC2a to TFIIIC2b and of TFIIIC110 to TFIIIC220 seen in transcriptionally active extracts from cells grown in the presence of E1A or high serum. However, these observations did not distinguish between cause and effect. The data are compatible with the possibility that selective loss of TFIIIC110 might occur as a consequence of down-regulated transcription, rather than having a causative role. For example, surplus TFIIIC might be degraded when active transcription is not occurring and TFIIIC110 might simply be less stable than the other subunits and therefore removed first, allowing accumulation of TFIIIC2b. Therefore, we tested the model directly by determining whether a specific induction of TFIIIC110 is sufficient to stimulate pol III transcription.

**MATERIALS AND METHODS**

**Cell culture**

HeLa and HEK293 cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. HeLa TET-ON cells were cultured in 10% FBS (tetracycline free), 100 U/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml G418. Stably transfected HeLa TET-ON cells were also supplemented with 100 μg/ml hygromycin. Expression of HA-TFIIIC110 and HA-Brf1 was induced by the addition of 1 μg/ml doxycycline for 48 h.

**HeLa cell proliferation assay**

Cells were plated on to 75 cm² flasks at a density of 5 x 10⁵ cells per plate, in media containing 0.5% or 10% FBS. Viable cells were counted every 24 h using trypan blue staining and a haemocytometer.

**Transient and stable transfection**

Transient transfection of HeLa and HEK293 cells were carried out using Lipofectamine. Stable transfection of HeLa TET-ON cells were also achieved using Lipofectamine. Stable transformants were selected using 200 μg/ml hygromycin.

**Plasmids**

pVA1 contains the adenovirus VA1 gene (24). pEGFP (Clontech) contains a cDNA encoding a derivative of green fluorescent protein expressed from a cytomegalovirus (CMV) promoter. pTRE2hygHA-Brf1 was produced by PCR amplification and sub-cloning into the pTRE2hyg vector (Clontech) the HA-Brf1 coding sequence from pcDNA3HA-Brf1 (25). Human TFIIIC110 was PCR amplified from the pRSET-TFIIIC110 vector (a kind gift from Robert Roeder) and subcloned into pcDNA3HA-TFIIIC110. HA-TFIIIC110 was subsequently subcloned into pTRE2hyg, again by PCR, to generate pTRE2hygHA-TFIIC110.

**Western blotting and antibodies**

Cells were washed twice with ice-cold phosphate-buffered saline (PBS) and scraped into lysis buffer [20 mM HEPES (pH 7.8), 150 mM NaCl, 25% glycerol, 50 mM NaF, 0.2 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 10 mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 0.5 μg/ml leupeptin, 1.0 μg/ml trypsin inhibitor, 0.5 μg/ml aprotinin and 40 μg/ml bestatin]. Lysates were incubated on ice for 10 min and passed through a 26-gauge needle three times, before centrifugation at 16 000 G for 10 min at 4°C. The supernatant was collected for immunoblot analysis, which was performed as described previously (26).

Antibodies were F-7 against HA, SI-1 against TFIIIB, C11 against actin and R-124 against cyclin D1 from Santa Cruz Biotechnologies. The Rb antibody G3-245 was from BD Pharmingen. Peptide antisera 128 against Brf, Ab4 against TFIIIC220, MTBP-6 against TBP and 1898 against TFIIIC90 have been described previously (7,23,25,27,28). Antibody 3208 against TFIIIC110 was raised by immunizing rabbits with synthetic peptide GEAPVGNNMTVVDSP (human TFIIIC110 residues 12-26) coupled to keyhole limpet haemocyanin.

**Immunoprecipitation**

Whole cell extracts (150 μg), prepared as described previously (26), were incubated in an orbital shaker for 3 h at 4°C with 30 μl of protein G beads carrying equivalent
 amounts of pre-bound IgG. Samples were pelleted and the beads washed five times with PBS. The bound material was analysed by western blotting.

Primer extension
Total RNA was extracted using TRI reagent, according to manufacturers’ instructions. RNA was then analysed by primer extension using labelled primers specific for VA1 5'-CACGCGGGCGGTAACCGCATG-3' and green fluorescent protein (GFP) 5'-CGTCGCCGTCCAGCTCGACCAG-3'. Primer extension assays were performed as described previously (20).

RT–PCR
RT–PCR analysis of ARPP P0 mRNA, 5S rRNA and tRNA transcripts were performed as described previously (29,30).

Northern blotting
Northern blotting was carried out as described previously (28). The ARPP P0 probe was a 1 kb EcoRI–HindIII fragment from the mouse cDNA (31). The tRNA probe was a 240 bp EcoRI–HindIII fragment from pLeu (32).

Immunofluorescence microscopy
Cells on coverslips were fixed in 4% para-formaldehyde in PBS for 10 min, followed by permeabilization in 0.1% Triton X-100 in PBS for 4 min. Cells were washed, blocked in 0.1% goat serum and 0.2% fish skin gelatin in PBS, before incubation with primary antibody (HA from Santa Cruz) at 1:100 or 1:500 dilution. Cells were again washed and blocked followed by incubation with secondary antibody (Alexa Fluor 488 goat anti-mouse IgG, from Molecular Probes) at 1:400 dilution. Cells were washed with PBS and mounted on to glass slides and viewed using a Zeiss Axiovert fluorescence microscope.

Chromatin immunoprecipitation (ChIP)
ChIP assays were carried out as described (33). The antibodies used were MTBP-6 against TBP (27), 4286 against TFIIIC110 (25), F-7 against HA and SI-1 against TFIIIB (both from Santa Cruz Biotechnologies). Primers and cycling parameters were as described previously (29,33). Serial dilutions of chromatin were used to confirm PCRs were within a linear range.

RESULTS
Transient transfection of a TFIIIC110 expression vector has minimal effect on pol III transcription in HeLa and HEK293 cells
A mammalian expression vector was constructed that allows overexpression of an mRNA encoding HA-tagged TFIIIC110. This construct was transiently transfected into HEK293 cells along with the adeno viral VA1 gene, the pol III-transcribed gene used in the original studies by Hoeffler, Kovelman and Roeder (5,12). A vector encoding GFP transcribed from the CMV promoter was cotransfected as a control for transfection efficiency. Western blotting for the HA tag confirmed that the exogenous TFIIIC110 protein was expressed in the transfected cells (Figure 2A). However, little or no effect was seen in multiple experiments on the level of VA1 transcript, as assayed by primer extension (Figure 2B and C).

Figure 2. Transient transfection of a HA-TFIIIC110 expression vector has little or no effect on VA1 transcript levels in HEK293 cells. (A) Western blot of HEK293 cells transfected with pcDNA3HA-TFIIIC110 and/or pcDNA3HA to a total concentration of 2 μg. Upper panel shows a blot for HA-TFIIIC110, lower panel shows a blot for actin. (B) Primer extension analysis of VA1 and GFP RNA in HEK293 cells transfected with 0.25 μg of each of the VA1 and GFP plasmids and with pcDNA3HA-TFIIIC110 and/or pcDNA3HA to a total concentration of 2 μg. (C) Quantitation of the data from (B) and three identical experiments.
transfection of the HA-TFIIC110 vector. We examined expression of 5S rRNA and tRNA genes, both of which require TFIIC for their transcription (1–3). No reproducible induction was observed for 5S rRNA, whereas tRNA showed a slight response of ~1.5-fold (Figure 3D and E). Although, this assay measures the steady-state level of 5S rRNA, our tRNA primers are specific for short-lived primary transcripts, which are considered to reflect the rate of ongoing transcription (29). This approach therefore provided limited support for the model that class III gene expression can be stimulated by a specific increase in the ratio of TFIIC110 to other TFIIC subunits.

Stable induction of TFIIC110 in HeLa cells has little effect on expression of tRNA and 5S rRNA

The experiments in Figure 3D and E measured levels of endogenous transcripts in the total cell population. However,
immunofluorescence analysis of GFP expression from the cotransfected control vector indicated that many of the HeLa cells remain untransfected under the conditions of our assays (data not shown). Since the presence of untransfected cells may partially mask a response, we produced HeLa cell clones that were stably transfected in the presence of a selectable marker, to ensure that the entire population receives the expression vector. The TFIIIC110 cDNA was subcloned into pTRE2hyg, which carries a doxycycline-responsive promoter. This was then used to produce multiple clones in which HA-tagged TFIIIC110 can be induced specifically by addition of doxycycline to the culture medium. Individual clones varied considerably in the levels of HA-TFIIIC110 that were produced (Figure 4A). We also observed clonal variation in the expression of tRNA and 5S rRNA (Figure 4B). However, RT–PCR analysis revealed no consistent change in the expression of pol III transcripts following induction of HA-TFIIIC110 (Figure 4B and C).

The model in Figure 1 predicts that pol III transcription might be more sensitive to TFIIIC110 induction under low serum conditions. Therefore, we cultured HeLa cells in 0.5% serum, as in the previous work (9,12). This treatment was sufficient to cause a marked reduction in cell proliferation (Figure 5A). Trypan blue staining did not reveal any substantial apoptosis (data not shown). As expected (32,34,35), tRNA expression was markedly diminished in low serum (Figure 5B). This was accompanied by a slight decrease in expression of endogenous TFIIIC110, as revealed by western blotting (Figure 5C). HA-TFIIIC110 remained inducible under these conditions (Figure 5D), but we again found that its induction has little or no effect on tRNA or 5S rRNA levels (Figure 5E and F).

Control experiments were conducted to verify that the exogenous HA-TFIIIC110 is incorporated into TFIIIC complexes. Sequence analysis using the PSORT II programme (http://psort.ims.u-tokyo.ac.jp) revealed a strong nuclear localization signal (NLS) in TFIIIC220, but not in the other TFIIIC subunits. Unincorporated HA-TFIIIC110 may therefore be retained in the cytoplasm. Indeed, cytoplasmic fluorescence was detected with antibody against the HA tag following addition of doxycycline to the stable transfectants (Figure 6A). However, an intense immunofluorescence signal was also observed from the nuclei. This is consistent with the possibility that although some of the induced protein may remain unincorporated and hence in the cytoplasm, a significant proportion associates with TFIIIC220 to form a complex that enters the nucleus. Complex assembly is supported by the finding that HA-TFIIIC110 can be coimmunoprecipitated from doxycycline-treated cells using antisera against TFIIIC220 (Figure 7A). Other TFIIIC subunits also associate with the HA-TFIIIC110, as shown by the fact that anti-HA antibody coimmunoprecipitates TFIIIC90 following doxycycline treatment (Figure 7B). This interaction is specific, since TFIIIC90 is not detected after control immunoprecipitations using antibodies against RB or cyclin D1. In addition, HA-TFIIIC110 is detected by ChIP at chromosomal tRNA and 5S rRNA genes, but not at the gene encoding TFIIIC220, which we used as a pol II-transcribed negative control (Figure 7C). In contrast, the pol II-specific transcription factor TFIIIB is detected at the TFIIIC220 gene, but not at tRNA or 5S rRNA genes, as expected. These data confirm that the doxycycline-induced exogenous HA-TFIIIC110 is incorporated into TFIIIC complexes that are recruited to the appropriate target genes in vivo. However, ChIP with an antibody that recognizes total TFIIIC110 (i.e. both endogenous and HA-tagged forms), shows no increase in gene occupancy in response to doxycycline (Figure 7C, lanes 3 and 4). The data suggest that although stable transfection with an inducible construct is able to raise the total level of TFIIIC110 in HeLa cells, it has little impact on the amount of this subunit that is assembled onto promoters. This is consistent with the lack of a significant transcriptional response.

![Figure 4](https://academic.oup.com/nar/article-abstract/34/11/3399/1067106)
Stable induction of Brf1 in HeLa cells can stimulate expression of tRNA and 5S rRNA

The data above show that specific induction of TFIIIC110 in HeLa cells has minimal effect on the expression of endogenous tRNA and 5S rRNA, even though the induced protein interacts with other TFIIIC subunits and is recruited to the appropriate template genes. Since this can be viewed as a negative result, it was necessary to confirm that the system we have used is amenable to transcriptional induction if a limiting factor is employed. We chose to try the Brf1 subunit of TFIIIB, as this has been shown to stimulate tRNA and 5S rRNA gene transcription when titrated into HeLa cell extracts. Therefore, we prepared stably transfected HeLa cell clones that carry doxycycline-inducible HA-tagged Brf1, using exactly the same approach as described above for HA-TFIIIC110. Blotting for the HA tag confirmed that HA-Brf1 can be induced in these cells by the addition of doxycycline (Figure 8A). A high proportion of this protein is localized to the nucleus (Figure 6B). Furthermore, RT–PCR analysis showed that tRNA and 5S rRNA levels are increased significantly in response to induction of HA-Brf1 (Figure 8B and C). This confirms that the doxycycline-regulated system used in these experiments can be exploited to activate pol III transcription. Therefore, we infer that a specific increase in the level of TFIIIC110 may not be an effective mechanism for pol III regulation in HeLa cells, as postulated.

DISCUSSION

In these experiments we have tested directly the model that TFIIIC110 is ‘a central controlling subunit’ for pol III
transcription of TFIIIC-dependent promoters, as suggested previously (9). Our data do not support this idea. A weak induction by TFIIIC110 was observed for the VA1 and tRNA genes in transiently transfected cells, but this was only around 1.5-fold. Furthermore, this small effect was not reproducible in stably transfected cells. 5S rRNA gene expression did not respond to TFIIIC110 induction under either circumstance. In contrast, induction of Brf1 produces a strong increase in tRNA and 5S rRNA expression under the same conditions. We have confirmed that the induced TFIIIC110 can interact with other TFIIIC subunits, enter the nucleus and be recruited specifically to target genes. However, this has little effect on the overall amounts of TFIIIC110 being recruited to chromosomal genes. The data suggest that this subunit is not limiting in the contexts we have investigated.

It was reported that several unidentified polypeptides co-purified with inactive TFIIIC2b and were not associated with active TFIIIC2a (5,9). In particular, a polypeptide of 77 kDa co-fractionated consistently with TFIIIC2b, although it was never detected by co-immunoprecipitation (9). As it was unclear whether this was a contaminant or had functional significance, the model of TFIIIC regulation by differential interaction with TFIIIC110 included the possibility that TFIIIC2b might contain an additional 77 kDa subunit as well as lacking TFIIIC110 (9). As far as we are aware, the identity of this putative subunit has not been reported. Clearly, the possibility of its involvement has not been addressed by our study.

Experiments carried out by Shen et al. lead them to question the existence of TFIIIC2b (7). These authors raised an antiserum against TFIIIC110 that, when used in an EMSA, was able to block all the DNA-binding activity of TFIIIC in a HeLa extract (7). This finding clearly conflicts with the report that a significant fraction of HeLa cell TFIIIC exists in a form (i.e. TFIIIC2b) that lacks TFIIIC110 but is undiminished in its DNA-binding capacity (5,12). We have been unable to address this issue because our antisera against TFIIIC110 are unable to block or supershift in an EMSA. Our study has specifically examined the hypothesis that selective induction of TFIIIC110 is a significant regulatory mechanism in vivo.
Another unresolved question with regard to mammalian TFIIIC concerns the identity of TFIIIC1, a TFIIIC-associated fraction that was found to be required for transcription of all types of pol III template using partially-purified reconstituted systems (36–41). Although candidate components of TFIIIC1 have been suggested (9,41), the functional significance of these polypeptides has not been demonstrated, as far as we are aware. Indeed, efficient pol III transcription of a U6 gene has been reconstituted more recently using a combination of recombinant and highly purified proteins without any TFIIIC1 fraction (42). It was suggested that TFIIIC1 might in fact correspond to Bdp1, an essential subunit of TFIIIB that dissociates readily during purification (42). This possibility is supported by the finding that Bdp1 co-fractionates with TFIIIC1 activity and can substitute for TFIIIC1 fractions in a reconstituted transcription assay (43).

The model of TFIIIC110 induction was proposed as a mechanism to explain the activation of pol III transcription by E1A and by serum (5,9,12). We have not examined whether E1A can selectively stimulate TFIIIC110 expression, but our data suggest that this would have little impact on transcriptional output, at least in HeLa cells. Other documented mechanisms may instead account for pol III activation under these circumstances. Yoshinaga et al. (16) demonstrated that overall levels of TFIIIC had increased 4- to 8-fold 30 h after adenovirus infection of HeLa cells. In addition, E1A can overcome RB-mediated repression of pol III transcription, both in vitro and in vivo (20). Serum stimulation leads to a phosphorylation-mediated inactivation of RB and so can also derepress the pol III machinery (44). Furthermore, pol III transcription is directly activated by c-Myc and Erk, both of which are serum-inducible (33,45). Combinations of these mechanisms may be sufficient to explain pol III responsiveness to E1A and to serum.

ACKNOWLEDGEMENTS

The authors thank Y. Shen and A. Berk for the Ab4 antibody, J. Flint for the MTBP-6 antibody and R. Roeder for the pRSET-TFIIIC110 vector. This work was funded by grant 068710 from the Wellcome Trust. Funding to pay the Open Access publication charges for this article was provided by grant 068710 from the Wellcome Trust.

Conflict of interest statement. None declared.

REFERENCES


